Novartis said pelacarsen failed to achieve its intended benefit in a Phase 3 cardiovascular outcomes study, raising stakes for other inflammation-targeting and lipid-adjacent programs. The Swiss pharma reported that pelacarsen was no better than control on the trial’s primary clinical endpoints, echoing a pattern of cardiovascular outcome misses among similar approaches. The setback follows recent high-profile cardiovascular trial disappointments across the sector, further challenging the notion that lowering certain disease drivers automatically produces reductions in major clinical complications. For remaining antisense and cardiometabolic developers, the pelacarsen result will likely sharpen scrutiny on target biology, patient selection, and endpoint sensitivity in the next generation of outcomes trials.